Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan

IRVING, Texas, Jan. 28, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient- centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Nature's npj Breast Cancer journal titled, "Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multiomic Molecular Profiling." Utilizing large-scale real-world clinico-genomic data and Caris's comprehensive multiomic profiling, Caris scientists uncovered clinically relevant mech ...